The therapeutic age of the neonatal Fc receptor
IgGs are essential soluble components of the adaptive immune response that evolved to
protect the body from infection. Compared with other immunoglobulins, the role of IgGs is …
protect the body from infection. Compared with other immunoglobulins, the role of IgGs is …
FcRn inhibitors: a novel option for the treatment of myasthenia gravis
LN Zhu, HM Hou, S Wang, S Zhang… - Neural Regeneration …, 2023 - journals.lww.com
Myasthenia gravis is an acquired, humoral immunity-mediated autoimmune disease
characterized by the production of autoantibodies that impair synaptic transmission at the …
characterized by the production of autoantibodies that impair synaptic transmission at the …
Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized …
JF Howard Jr, V Bril, T Vu, C Karam, S Peric… - Frontiers in …, 2024 - frontiersin.org
Objective ADAPT+ assessed the long-term safety, tolerability, and efficacy of efgartigimod in
adult participants with generalized myasthenia gravis (gMG). Methods ADAPT+ was an …
adult participants with generalized myasthenia gravis (gMG). Methods ADAPT+ was an …
Batoclimab vs placebo for generalized myasthenia gravis: A randomized clinical trial
C Yan, Y Yue, Y Guan, B Bu, Q Ke, R Duan… - JAMA …, 2024 - jamanetwork.com
Importance Myasthenia gravis (MG) is caused by autoantibodies that disrupt the
neuromuscular junction. The neonatal fragment crystallizable receptor (FcRn) antagonists …
neuromuscular junction. The neonatal fragment crystallizable receptor (FcRn) antagonists …
[HTML][HTML] Quantification of clesrovimab, an investigational, half-life extended, anti-respiratory syncytial virus protein F human monoclonal antibody in the nasal epithelial …
JY Phuah, BM Maas, A Tang, Y Zhang, L Caro… - Biomedicine & …, 2023 - Elsevier
Abstract Background Clesrovimab (MK-1654) is an investigational, half-life extended human
monoclonal antibody (mAb) against RSV F glycoprotein in clinical trials as a prophylactic …
monoclonal antibody (mAb) against RSV F glycoprotein in clinical trials as a prophylactic …
Blood–urea–nitrogen-to-serum–albumin ratio in predicting the value of patients with contrast-induced nephropathy for coronary heart disease
Q Pan, Y Peng, H Ni, L Lin, B Luo, X Huang… - … Urology and Nephrology, 2024 - Springer
Background The blood–urea–nitrogen (BUN)-to-serum–albumin (ALB) ratio (BAR) has been
identified as a novel indicator of both inflammatory and nutritional status, exhibiting a …
identified as a novel indicator of both inflammatory and nutritional status, exhibiting a …
[HTML][HTML] Therapeutic plasma exchange versus FcRn inhibition in autoimmune disease
Therapeutic plasma exchange (TPE or PLEX) is used in a broad range of autoimmune
diseases, with the goal of removing autoantibodies from the circulation. A newer approach …
diseases, with the goal of removing autoantibodies from the circulation. A newer approach …
[HTML][HTML] Exploiting the neonatal Fc receptor to treat kidney disease
JF Dylewski, G Haddad, J Blaine - Kidney International, 2023 - Elsevier
Abstract The neonatal Fc receptor (FcRn) was initially discovered as the receptor that
allowed passive immunity in newborns by transporting maternal IgG through the placenta …
allowed passive immunity in newborns by transporting maternal IgG through the placenta …
Effect of efgartigimod on muscle group subdomains in participants with generalized myasthenia gravis: post hoc analyses of the phase 3 pivotal ADAPT study
V Bril, JF Howard Jr, C Karam… - European Journal of …, 2024 - Wiley Online Library
Background and purpose Generalized myasthenia gravis (gMG) is a rare, chronic,
neuromuscular autoimmune disease mediated by pathogenic immunoglobulin G (IgG) …
neuromuscular autoimmune disease mediated by pathogenic immunoglobulin G (IgG) …